AKT1 and breast cancer: In the ISPY-2 breast cancer trial, higher levels of Akt substrate phosphorylation in HER2+ tumors are associated with better response to MK2206, whereas lower levels of Akt pathway phosphoproteins correlate with better response in TNBC [238].